# ZD6474(Vandetanib) + Alimta Combo Study

> **NCT00506051** · PHASE1 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 21 (actual)

## Conditions studied

- Carcinoma
- Non-Small Cell Lung
- Lung Cancer

## Interventions

- **DRUG:** ZD6474 (vandetanib) 100mg
- **DRUG:** pemetrexed
- **DRUG:** ZD6474 (vandetanib) 300mg

## Key facts

- **NCT ID:** NCT00506051
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** 2006-05
- **Final completion:** 2011-10
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2016-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00506051

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00506051, "ZD6474(Vandetanib) + Alimta Combo Study". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00506051. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*